NCRI 2016: Five reasons why we must prioritise innovative drug discovery to tackle cancer’s challenges 07 Nov 2016 ICR Chief Executive Professor Paul Workman took part in a debate at the NCRI conference on how to prioritise research spending — on creating new treatments or repurposing old ones. Here he outlines the arguments in favour of innovation. Find out more Show/Hide